Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Dyadic International Inc's Business Segments
Dyadic International Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Grant
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Grant0%
- Non Us0%
- License22.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 1 | - |
| Non Us | $ 1 | - |
| License | $ 0 | 22.9% |
Revenue by Product & Service Category - FY
- Grant43.8%
- License19.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 0 | 43.8% |
| License | $ 0 | 19.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Grant0%
- Non Us0%
- License22.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 1 | - |
| Non Us | $ 1 | - |
| License | $ 0 | 22.9% |
Description of Dyadic International Inc
Dyadic International Inc.
(DYAI) is a biotechnology company based in Jupiter, Florida, USA.
It specializes in developing and implementing advanced technology solutions for the discovery, development, and production of biologics such as vaccines, monoclonal antibodies, and biosimilars.
Dyadic's technology platform is based on its proprietary C1 gene expression technology which is capable of producing high levels of proteins and enzymes at a low cost.
The C1 platform is scalable, adaptable and has numerous applications in various industries including biopharmaceuticals, animal health, industrial enzymes, and biofuels.
Dyadic has established collaborations with several leading global biotech and pharmaceutical companies to develop and produce a wide range of biologics.
The company is also engaged in research and development to enhance its technology platform and expand its applications.
In addition to its biotechnology operations, Dyadic is also exploring opportunities in other related fields, including developing sustainable and environmentally-friendly products that are derived from its C1 technology.
Dyadic International Inc.
was founded in 1979 and went public in 2005.
The company has a team of over 90 employees and is led by CEO Mark Emalfarb.
It trades on the NASDAQ under the ticker symbol DYAI.
(DYAI) is a biotechnology company based in Jupiter, Florida, USA.
It specializes in developing and implementing advanced technology solutions for the discovery, development, and production of biologics such as vaccines, monoclonal antibodies, and biosimilars.
Dyadic's technology platform is based on its proprietary C1 gene expression technology which is capable of producing high levels of proteins and enzymes at a low cost.
The C1 platform is scalable, adaptable and has numerous applications in various industries including biopharmaceuticals, animal health, industrial enzymes, and biofuels.
Dyadic has established collaborations with several leading global biotech and pharmaceutical companies to develop and produce a wide range of biologics.
The company is also engaged in research and development to enhance its technology platform and expand its applications.
In addition to its biotechnology operations, Dyadic is also exploring opportunities in other related fields, including developing sustainable and environmentally-friendly products that are derived from its C1 technology.
Dyadic International Inc.
was founded in 1979 and went public in 2005.
The company has a team of over 90 employees and is led by CEO Mark Emalfarb.
It trades on the NASDAQ under the ticker symbol DYAI.
Dyadic International Inc. is a prominent global biotech company that harnesses its proprietary C1 fungus expression platform for the development and manufacturing of an array of biopharmaceuticals, vaccines, and industrial enzymes, thus catering to multiple sectors. The companys offerings are categorized into three main segments: Biopharmaceuticals, Industrial Enzymes, and Contract Research Services. Below is an extensive description of each segment, along with the respective products and services.
1. Biopharmaceuticals
The Biopharmaceuticals segment of Dyadic International focuses on the creation and production of effective and safe protein-based therapeutics aimed at enhancing human health. The C1 technology is instrumental in facilitating the rapid and cost-effective manufacturing of intricate proteins, which plays a crucial role in the development of various therapeutic modalities.
Key Products:
- DYAI-100: This is a fully-human antibody therapeutic designed for treating various forms of solid tumors as well as blood cancers. Its development is indicative of Dyadics commitment to address serious medical conditions through innovative therapeutic solutions.
- COVID-19 Vaccine: Dyadic is actively developing a vaccine candidate against COVID-19 utilizing its C1 platform technology. The aim is to create an effective and accessible vaccine to aid in combating the pandemic, marking the company’s engagement in global health initiatives.
- Biosimilars: The company is leveraging its C1 technology to produce biosimilars, which are biologics highly similar to existing approved reference products. These biosimilars present a cost-effective alternative to expensive biologic drugs that have recently gone off patent. By doing so, Dyadic aims to enhance patient access to essential therapies.
Industrial Enzymes
The Industrial Enzymes segment is dedicated to the development and manufacturing of high-performance enzymes targeted at various industrial applications. The C1 technology is utilized to produce enzymes that demonstrate enhanced efficiency, applicable in sectors such as biofuels, food production, animal nutrition, and pulp and paper manufacturing.
Key Products:
- AlternaFuele CMAXe: This enzyme significantly enhances the efficiency of cellulosic ethanol production, thereby reducing production costs and improving yield. Its application contributes positively to the biofuels market by promoting more sustainable production methods.
- FibreZymee G500: Developed for the pulp and paper industry, this enzyme improves bleaching processes, leading to heightened efficiency and a diminished environmental impact, showcasing Dyadics commitment to sustainability.
- Glycoswitche: This enzyme platform focuses on improving the quality and yield of various food and beverage products, particularly beneficial in the production of plant-based alternatives. It illustrates Dyadics role in the advancement of health-conscious consumer products.
Contract Research Services
Dyadics Contract Research Services segment provides customized solutions to clients in the biopharmaceutical, enzyme, and industrial sectors. The company offers a comprehensive range of services designed to expedite product development while minimizing costs.
Key Services:
- Gene Expression: Dyadic provides services such as gene synthesis, cloning, and expression for both standard and complex proteins. This service is essential for clients seeking to explore and exploit protein functionality.
- Strain Development: Utilizing the C1 technology allows Dyadic to optimize strains efficiently, which enhances protein production yields. This aspect is critical for clients aiming to improve their production processes.
- Process Development: Dyadic offers tailored process development services aimed at optimizing the purification, formulation, and characterization of proteins. Additionally, the company provides tech transfer support, assisting clients in transitioning from discovery phases to larger-scale production.
Conclusion
In summary, Dyadic International Inc. presents a comprehensive suite of products and services organized into three main segments: Biopharmaceuticals, Industrial Enzymes, and Contract Research Services. Each segment emphasizes the innovative use of the proprietary C1 platform technology, reflecting Dyadic’s dedication to developing and manufacturing biologics, vaccines, and enzymes for diverse industries. Through its innovative solutions, the company positions itself as a key player in the biotechnology landscape, addressing significant health and industrial challenges.
1. Biopharmaceuticals
The Biopharmaceuticals segment of Dyadic International focuses on the creation and production of effective and safe protein-based therapeutics aimed at enhancing human health. The C1 technology is instrumental in facilitating the rapid and cost-effective manufacturing of intricate proteins, which plays a crucial role in the development of various therapeutic modalities.
Key Products:
- DYAI-100: This is a fully-human antibody therapeutic designed for treating various forms of solid tumors as well as blood cancers. Its development is indicative of Dyadics commitment to address serious medical conditions through innovative therapeutic solutions.
- COVID-19 Vaccine: Dyadic is actively developing a vaccine candidate against COVID-19 utilizing its C1 platform technology. The aim is to create an effective and accessible vaccine to aid in combating the pandemic, marking the company’s engagement in global health initiatives.
- Biosimilars: The company is leveraging its C1 technology to produce biosimilars, which are biologics highly similar to existing approved reference products. These biosimilars present a cost-effective alternative to expensive biologic drugs that have recently gone off patent. By doing so, Dyadic aims to enhance patient access to essential therapies.
Industrial Enzymes
The Industrial Enzymes segment is dedicated to the development and manufacturing of high-performance enzymes targeted at various industrial applications. The C1 technology is utilized to produce enzymes that demonstrate enhanced efficiency, applicable in sectors such as biofuels, food production, animal nutrition, and pulp and paper manufacturing.
Key Products:
- AlternaFuele CMAXe: This enzyme significantly enhances the efficiency of cellulosic ethanol production, thereby reducing production costs and improving yield. Its application contributes positively to the biofuels market by promoting more sustainable production methods.
- FibreZymee G500: Developed for the pulp and paper industry, this enzyme improves bleaching processes, leading to heightened efficiency and a diminished environmental impact, showcasing Dyadics commitment to sustainability.
- Glycoswitche: This enzyme platform focuses on improving the quality and yield of various food and beverage products, particularly beneficial in the production of plant-based alternatives. It illustrates Dyadics role in the advancement of health-conscious consumer products.
Contract Research Services
Dyadics Contract Research Services segment provides customized solutions to clients in the biopharmaceutical, enzyme, and industrial sectors. The company offers a comprehensive range of services designed to expedite product development while minimizing costs.
Key Services:
- Gene Expression: Dyadic provides services such as gene synthesis, cloning, and expression for both standard and complex proteins. This service is essential for clients seeking to explore and exploit protein functionality.
- Strain Development: Utilizing the C1 technology allows Dyadic to optimize strains efficiently, which enhances protein production yields. This aspect is critical for clients aiming to improve their production processes.
- Process Development: Dyadic offers tailored process development services aimed at optimizing the purification, formulation, and characterization of proteins. Additionally, the company provides tech transfer support, assisting clients in transitioning from discovery phases to larger-scale production.
Conclusion
In summary, Dyadic International Inc. presents a comprehensive suite of products and services organized into three main segments: Biopharmaceuticals, Industrial Enzymes, and Contract Research Services. Each segment emphasizes the innovative use of the proprietary C1 platform technology, reflecting Dyadic’s dedication to developing and manufacturing biologics, vaccines, and enzymes for diverse industries. Through its innovative solutions, the company positions itself as a key player in the biotechnology landscape, addressing significant health and industrial challenges.